1251529-07-3 Usage
General Description
1-(4-chloro-3-methyl-benzyl)-piperidin-4-one is an organic compound with the molecular formula C14H18ClNO. It is a piperidinone derivative, which is a class of organic compounds containing a piperidine ring with a ketone functional group. This specific compound features a piperidine ring with a 4-chloro-3-methyl-benzyl group attached to it and a ketone group at the 4 position on the piperidine ring. It is used in pharmaceutical research and development, particularly in the synthesis of new drugs and drug candidates. 1-(4-chloro-3-methyl-benzyl)-piperidin-4-one may have potential therapeutic applications due to its chemical structure and functional groups, and it is of interest to chemists and pharmacologists studying the structure-activity relationships of biologically active molecules.
Check Digit Verification of cas no
The CAS Registry Mumber 1251529-07-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,1,5,2 and 9 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1251529-07:
(9*1)+(8*2)+(7*5)+(6*1)+(5*5)+(4*2)+(3*9)+(2*0)+(1*7)=133
133 % 10 = 3
So 1251529-07-3 is a valid CAS Registry Number.
1251529-07-3Relevant articles and documents
PROCESS FOR THE MANUFACTURING OF CRR INHIBITORS
-
Paragraph 0089, (2013/10/08)
The present invention relates to a process for preparing CCR3 inhibitors of formula 1, wherein R1 is H, C1-6-alkyl, C0-4-alkyl-C3-6-cycloalkyl, C1-6-haloalkyl; R2 is H, C1-6-alky
CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS
-
Page/Page column 8, (2012/10/23)
This invention relates to co-crystals and salts of CCR3 inhibitors of formula 1, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases related with the CCR3-receptor.
SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS
-
Page/Page column 38, (2010/11/03)
Object of the present invention are novel substituted compounds of the formula 1, wherein A, R1, R2, R3 and R4 are defined as in the description. Another object of the present invention is to provide antagonists of CCR3, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
